Novophage
Boston
About Novophage
Novophage is providing the biological solutions for industrial infrastructure problems. Biofilms, slimy communities of bacteria, prevent heat transfer, cause massive corrosion, biofouling and diseases, while costing the US economy in the double-digit billion dollar figures. Current approaches to combat these persistent problems are either toxic, corrosive and/or environmentally damaging. Novophage is developing a first-in-class anti-biofilm solution that is green and highly effective against biofilms. Enabled by their expertise in synthetic biology and systems biology, their patent-pending solution utilizes a biological nanoparticle that leverages biofilm bacteria’s own machinery to create active agents that act against the biofilm itself. This approach can be combined with existing antimicrobials to increase energy efficiency in heat transfer systems and prolong the lifetime of valuable infrastructure.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2011)
- Website: novophage.com
Industries & Categories
Biotechnology, Industrial, Information Technology, Infrastructure, Renewable Energy
Social Profiles
Canonical: https://fsome.com/organization/novophage-3337232 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.